HIT PE Ratio & Valuation,Is HIT Overvalued

HIT Relative Valuation

HIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HIT is overvalued; if below, it's undervalued.

Historical Valuation

Health In Tech Inc (HIT) is now in the Fair zone, suggesting that its current forward PE ratio of 19.27 is considered Fairly compared with the five-year average of 22.07. The fair price of Health In Tech Inc (HIT) is between 0.57 to 2.27 according to relative valuation methord.

Relative Value

Fair Zone

0.57-2.27

Current Price：1.23

Fair

19.27

12.33

EV/EBITDA

Health In Tech Inc. (HIT) has a current EV/EBITDA of 12.33. The 5-year average EV/EBITDA is 12.58. The thresholds are as follows: Strongly Undervalued below -14.94, Undervalued between -14.94 and -1.18, Fairly Valued between 26.34 and -1.18, Overvalued between 26.34 and 40.09, and Strongly Overvalued above 40.09. The current Forward EV/EBITDA of 12.33 falls within the Historic Trend Line -Fairly Valued range.

74.62

EV/EBIT

Health In Tech Inc. (HIT) has a current EV/EBIT of 74.62. The 5-year average EV/EBIT is 54.64. The thresholds are as follows: Strongly Undervalued below -105.82, Undervalued between -105.82 and -25.59, Fairly Valued between 134.87 and -25.59, Overvalued between 134.87 and 215.11, and Strongly Overvalued above 215.11. The current Forward EV/EBIT of 74.62 falls within the Historic Trend Line -Fairly Valued range.

1.55

Health In Tech Inc. (HIT) has a current PS of 1.55. The 5-year average PS is 2.16. The thresholds are as follows: Strongly Undervalued below -1.03, Undervalued between -1.03 and 0.56, Fairly Valued between 3.76 and 0.56, Overvalued between 3.76 and 5.36, and Strongly Overvalued above 5.36. The current Forward PS of 1.55 falls within the Historic Trend Line -Fairly Valued range.

9.62

P/OCF

Health In Tech Inc. (HIT) has a current P/OCF of 9.62. The 5-year average P/OCF is 13.21. The thresholds are as follows: Strongly Undervalued below -13.80, Undervalued between -13.80 and -0.30, Fairly Valued between 26.71 and -0.30, Overvalued between 26.71 and 40.21, and Strongly Overvalued above 40.21. The current Forward P/OCF of 9.62 falls within the Historic Trend Line -Fairly Valued range.

18.45

P/FCF

Health In Tech Inc. (HIT) has a current P/FCF of 18.45. The 5-year average P/FCF is 30.46. The thresholds are as follows: Strongly Undervalued below -31.46, Undervalued between -31.46 and -0.50, Fairly Valued between 61.42 and -0.50, Overvalued between 61.42 and 92.38, and Strongly Overvalued above 92.38. The current Forward P/FCF of 18.45 falls within the Historic Trend Line -Fairly Valued range.

Health In Tech Inc (HIT) has a current Price-to-Book (P/B) ratio of 3.49. Compared to its 3-year average P/B ratio of 11.33 , the current P/B ratio is approximately -69.21% higher. Relative to its 5-year average P/B ratio of 11.33, the current P/B ratio is about -69.21% higher. Health In Tech Inc (HIT) has a Forward Free Cash Flow (FCF) yield of approximately 3.57%. Compared to its 3-year average FCF yield of 4.28%, the current FCF yield is approximately -16.61% lower. Relative to its 5-year average FCF yield of 4.28% , the current FCF yield is about -16.61% lower.

3.49

P/B

Median3y

11.33

Median5y

11.33

3.57

FCF Yield

Median3y

4.28

Median5y

4.28

Competitors Valuation Multiple

The average P/S ratio for HIT's competitors is 0.83, providing a benchmark for relative valuation. Health In Tech Inc Corp (HIT) exhibits a P/S ratio of 1.55, which is 86.47% above the industry average. Given its robust revenue growth of 90.41%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of HIT decreased by 80.80% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 4.46M to 8.49M.

The secondary factor is the Margin Expansion, contributed -36.77%to the performance.

Overall, the performance of HIT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

90.41%

4.46M → 8.49M

Revenue Growth

-36.77%

8.43 → 5.33

Margin Expansion

-134.44%

-145.52 → 50.12

P/E Change

-80.80%

5.52 → 1.06

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Health In Tech Inc (HIT) currently overvalued or undervalued?

What is Health In Tech Inc (HIT) fair value?

HIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Health In Tech Inc (HIT) is between 0.57 to 2.27 according to relative valuation methord.

How does HIT's valuation metrics compare to the industry average?

What is the current P/B ratio for Health In Tech Inc (HIT) as of Dec 15 2025?

As of Dec 15 2025, Health In Tech Inc (HIT) has a P/B ratio of 3.49. This indicates that the market values HIT at 3.49 times its book value.

What is the current FCF Yield for Health In Tech Inc (HIT) as of Dec 15 2025?

As of Dec 15 2025, Health In Tech Inc (HIT) has a FCF Yield of 3.57%. This means that for every dollar of Health In Tech Inc’s market capitalization, the company generates 3.57 cents in free cash flow.

What is the current Forward P/E ratio for Health In Tech Inc (HIT) as of Dec 15 2025?

As of Dec 15 2025, Health In Tech Inc (HIT) has a Forward P/E ratio of 19.27. This means the market is willing to pay $19.27 for every dollar of Health In Tech Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Health In Tech Inc (HIT) as of Dec 15 2025?

As of Dec 15 2025, Health In Tech Inc (HIT) has a Forward P/S ratio of 1.55. This means the market is valuing HIT at $1.55 for every dollar of expected revenue over the next 12 months.

HIT Valuation